



JEB BUSH, GOVERNOR

RHONDA M. MEDOWS, MD, FAAFP, SECRETARY

October 19, 2001

Dear Prescriber:

This letter is to inform you of an important change to the Medicaid program. The following Novolin brand insulins: Novolin 70/30, Novolin N, Novolin R and Novolin L are included in the Medicaid Preferred Drug List (PDL) and are available without prior authorization.

This change affects recipients who use the following insulins: Humulin 70/30, Humulin N, Humulin R and Humulin L. Effective November 15, 2001, these insulins will require prior authorization. After November 15, 2001, any prescriptions for these insulins that have not been prior authorized will be denied. Other forms of insulin are not affected by this change and will not require authorization.

If you feel there is justification for specific recipients to use a brand other than the Novolin brand for these four forms of insulin you may contact the Medicaid fiscal agent at (877) 553-7481 to request authorization for that recipient.

All recipients who routinely receive these insulins and their pharmacists have been notified of this prior authorization requirement. Medicaid pharmacy providers have been asked to notify any prescribers they may encounter who have not been advised of this change.

For additional information, please contact Medicaid Pharmacy Services at (850) 487-4441.

Sincerely,

A handwritten signature in black ink that reads "George J. Kitchens".

George Kitchens, R.Ph.
Chief, Medicaid Pharmacy Services

A handwritten signature in black ink that reads "J. Darrell Shea".

J. Darrell Shea, M.D.
Chief Medical Officer

